PRECISION BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On January 6, 2025, we issued 220,712 shares of our common stock to TG Subsidiary in exchange for the deferred cash payment of $2.5 million that was paid to the Company as partial consideration for the license rights we granted to TG Therapeutics pursuant to the
TG License Agreement. The issuance of the shares to TG Subsidiary was not registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) thereunder.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.